EMERGENT BIOSOLUTIONS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.41 USD | +0.23% |
|
+128.50% | +83.75% |
| May. 02 | Sector Update: Health Care Stocks Softer Late Afternoon | MT |
| May. 02 | Sector Update: Health Care | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,785 | 4,749 | 2,339 | 589.2 | 124.5 | 231.1 | - | - |
| Enterprise Value (EV) 1 | 3,428 | 5,002 | 2,603 | 1,352 | 873 | 342.3 | 567.1 | 589.2 |
| P/E ratio | 51.9 x | 15.8 x | 10.2 x | -2.64 x | -0.16 x | -1.47 x | -2.09 x | -2.08 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 2.52 x | 3.05 x | 1.3 x | 0.53 x | 0.12 x | 0.23 x | 0.2 x | 0.2 x |
| EV / Revenue | 3.1 x | 3.22 x | 1.45 x | 1.21 x | 0.83 x | 0.34 x | 0.5 x | 0.52 x |
| EV / EBITDA | 12.3 x | 7.94 x | 5.03 x | 51.8 x | -39.1 x | 4.56 x | - | - |
| EV / FCF | 33.9 x | 12.7 x | 27.1 x | -9.02 x | -3.39 x | 1.57 x | 6.67 x | - |
| FCF Yield | 2.95% | 7.9% | 3.69% | -11.1% | -29.5% | 63.7% | 15% | - |
| Price to Book | 2.55 x | 3.29 x | 1.38 x | 0.43 x | 0.19 x | 0.44 x | 0.53 x | 0.67 x |
| Nbr of stocks (in thousands) | 51,624 | 52,999 | 53,799 | 49,888 | 51,884 | 52,402 | - | - |
| Reference price 2 | 53.95 | 89.60 | 43.47 | 11.81 | 2.400 | 4.410 | 4.410 | 4.410 |
| Announcement Date | 2/20/20 | 2/18/21 | 2/24/22 | 2/27/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,106 | 1,555 | 1,793 | 1,121 | 1,049 | 1,015 | 1,138 | 1,143 |
| EBITDA 1 | 279.7 | 630.4 | 517.6 | 26.1 | -22.3 | 75 | - | - |
| EBIT 1 | 114.1 | 433.8 | 352.6 | -172.7 | -726.4 | -88.65 | -69.51 | -95.26 |
| Operating Margin | 10.32% | 27.89% | 19.67% | -15.41% | -69.23% | -8.73% | -6.11% | -8.33% |
| Earnings before Tax (EBT) 1 | 77.4 | 407.2 | 314.4 | -221.7 | -731.2 | -160.1 | -110.3 | -112.3 |
| Net income 1 | 54.5 | 305.1 | 230.9 | -223.8 | -760.5 | -155.5 | -110.3 | -112.3 |
| Net margin | 4.93% | 19.62% | 12.88% | -19.97% | -72.48% | -15.31% | -9.7% | -9.82% |
| EPS 2 | 1.040 | 5.670 | 4.270 | -4.470 | -14.85 | -2.993 | -2.106 | -2.123 |
| Free Cash Flow 1 | 101.1 | 395 | 96.1 | -149.9 | -257.9 | 218 | 85 | - |
| FCF margin | 9.14% | 25.4% | 5.36% | -13.37% | -24.58% | 21.47% | 7.47% | - |
| FCF Conversion (EBITDA) | 36.15% | 62.66% | 18.57% | - | - | 290.67% | - | - |
| FCF Conversion (Net income) | 185.5% | 129.47% | 41.62% | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 2/20/20 | 2/18/21 | 2/24/22 | 2/27/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 723.2 | 307.5 | 242.7 | 240 | 330.7 | 165.1 | 337.9 | 270.5 | 276.6 | 300.4 | 221.8 | 306.5 | 266.5 |
| EBITDA 1 | 347.9 | 36 | -28.8 | -15.2 | 34.2 | -100.8 | 55.9 | 19.8 | 3.4 | 66.9 | 9.5 | 28 | 43 |
| EBIT 1 | 277.4 | 6.4 | -72 | -42 | -65.1 | -148.1 | 13.8 | -242.1 | -43.8 | 39.8 | -37.75 | 2.5 | -12.5 |
| Operating Margin | 38.36% | 2.08% | -29.67% | -17.5% | -19.69% | -89.7% | 4.08% | -89.5% | -15.84% | 13.25% | -17.02% | 0.82% | -4.69% |
| Earnings before Tax (EBT) 1 | 267.5 | -3.8 | -82.8 | -63.9 | -71.2 | -161.1 | -250.2 | -265.9 | -54.5 | 12.1 | -56 | -15.25 | -30.25 |
| Net income 1 | 189.3 | -3.7 | -56.4 | -75.7 | -88 | -183 | -261.3 | -263.4 | -49.5 | 9 | -45.5 | -32 | -22 |
| Net margin | 26.18% | -1.2% | -23.24% | -31.54% | -26.61% | -110.84% | -77.33% | -97.38% | -17.9% | 3% | -20.52% | -10.44% | -8.26% |
| EPS 2 | 3.500 | -0.0700 | -1.130 | -1.520 | -1.760 | -3.650 | -5.150 | -5.080 | -0.9500 | 0.1700 | -1.052 | -0.2732 | -0.5612 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/22 | 4/28/22 | 8/1/22 | 11/8/22 | 2/27/23 | 5/9/23 | 8/8/23 | 11/8/23 | 3/6/24 | 5/1/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 643 | 254 | 265 | 763 | 749 | 111 | 336 | 358 |
| Net Cash position 1 | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | 2.3 x | 0.4024 x | 0.5114 x | 29.24 x | -33.57 x | 1.483 x | - | - |
| Free Cash Flow 1 | 101 | 395 | 96.1 | -150 | -258 | 218 | 85 | - |
| ROE (net income / shareholders' equity) | 14.5% | 33.4% | 21.2% | -7.46% | -31.3% | -17.7% | -12.6% | -16.6% |
| ROA (Net income/ Total Assets) | 6.68% | 16.3% | 11.1% | -3.65% | -12.8% | -5.9% | -4.16% | -5.45% |
| Assets 1 | 815.9 | 1,875 | 2,071 | 6,126 | 5,947 | 2,638 | 2,653 | 2,062 |
| Book Value Per Share 2 | 21.10 | 27.30 | 31.60 | 27.60 | 12.40 | 9.970 | 8.250 | 6.550 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 86.9 | 141 | 225 | 116 | 51.6 | 30 | 30 | - |
| Capex / Sales | 7.86% | 9.07% | 12.55% | 10.33% | 4.92% | 2.95% | 2.64% | - |
| Announcement Date | 2/20/20 | 2/18/21 | 2/24/22 | 2/27/23 | 3/6/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
4.41
USD
Average target price
5
USD
Spread / Average Target
+13.38%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +83.75% | 231M | |
| +32.95% | 698B | |
| +26.51% | 568B | |
| -4.97% | 358B | |
| +18.83% | 328B | |
| +3.54% | 283B | |
| +15.70% | 238B | |
| +6.68% | 203B | |
| -9.08% | 198B | |
| +6.70% | 165B |
- Stock Market
- Equities
- EBS Stock
- Financials Emergent BioSolutions Inc.